Skip to main content

Table 3 Pharmacokinetic parameters following a 150 mg/kg taurolidine infusion over 2 hrs

From: Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma

ID Cmax (ug/mL) Tmax (hr) Lambda_z (1/hr) t1/2 (hr) AUClast (hr*ug/mL) AUCINF (hr*ug/mL) CL (L/hr/kg) Vss (L/kg) MRT (hr)
1 65.6 1.50 0.192 3.6 178 197 0.763 3.11 4.1
2 144.8 2.00 0.203 3.4 667 680 0.221 0.85 3.9
3 185.0 1.50 0.201 3.5 457 467 0.321 0.97 3.0
4 145.1 1.25 0.201 3.4 337 339 0.442 1.26 2.8
5 162.5 2.08 0.183 3.8 684 698 0.215 1.09 5.1
6 139.7 1.75 0.272 2.6 346 348 0.431 1.09 2.5
Mean 140.5 1.63* 0.209 3.4 445 455 0.399 1.39 3.6
SD 40.3 NA 0.032 0.4 200 201 0.204 0.85 0.9
CV% 28.7 NA 15.3 12.7 44.9 44.1 51.0 60.9 26.5
  1. *median; Cmax Maximum concentration, Tmax Time to Cmax, t1/2 serum half-life, AUClast area under the curve to last quantifiable concentration, AUCINF Area under the serum concentration-time profile from time zero, CL Clearance, Vss Volume of distribution at steady state, and MRT Mean residence time.